Sugi Predict

Sugi Predict / Compounds / SCHEMBL631074

SCHEMBL631074

SCHEMBL631074

COC(=O)COc1ccc(NC(=O)N2CCN(c3ccccc3C(C)(C)C)CC2)cc1

nearest known ligand 0.69

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ RBP4 P02753 7/20 0.69
▸ TRPV1 Q8NER1 2/20 0.50
▸ MEN1 O00255 1/20 0.50
▸ KMT2A Q03164 1/20 0.50
▸ CA2 P00918 2/20 0.49
▸ CA9 Q16790 2/20 0.49
▸ MAPT P10636 1/20 0.48
▸ GOT1 P17174 1/20 0.48
▸ TSHR P16473 1/20 0.48
▸ CA12 O43570 1/20 0.47
▸ CA1 P00915 1/20 0.47
▸ POLB P06746 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL766225 0.91 RBP4 (0.73) RBP4TRPV1MEN1KMT2ACA2
SCHEMBL766472 0.90 RBP4 (0.54) RBP4MEN1KMT2ATSHRPOLB
SCHEMBL630971 0.86 RBP4 (0.72) RBP4TRPV1MEN1KMT2ACA2
SCHEMBL631731 0.85 RBP4 (0.65) RBP4MEN1KMT2AMAPTTSHR
SCHEMBL3723299 0.83 RBP4 (0.74) RBP4TRPV1MEN1KMT2ACA2
SCHEMBL27873728 0.83 RBP4 (0.67) RBP4TRPV1MEN1KMT2ACA2
SCHEMBL30996953 0.82 RBP4 (1.00) RBP4TRPV1MEN1KMT2AMAPT
SCHEMBL630718 0.82 RBP4 (1.00) RBP4TRPV1MEN1KMT2AMAPT
SCHEMBL631664 0.81 RBP4 (0.83) RBP4TRPV1MEN1KMT2ACA2
SCHEMBL3723297 0.81 RBP4 (0.71) RBP4TRPV1MEN1KMT2ACA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2419413-B1 DERIVATIVES OF N-ACYL-N'-PHENYLPIPERAZINE USEFUL (INTER ALIA) FOR THE PROPHYLAXIS OR TREATMENT OF DIABETES TAKEDA PHARMACEUTICAL (JP) 2016-11-23 — — EP disclosed
US-8853215-B2 Derivatives of N-acyl-N′-phenylpiperazine useful (inter alia) for the prophylaxis or treatment of diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-10-07 — — US disclosed
CN-102459209-A Derivatives of N-acyl-N' -phenylpiperazines for the prevention or treatment of diabetes (etc.) TAKEDA PHARMACEUTICAL 2012-05-16 — — CN disclosed
US-20120071489-A1 DERIVATIVES OF N-ACYL-N'-PHENYLPIPERAZINE USEFUL (INTER ALIA) FOR THE PROPHYLAXIS OR TREATMENT OF DIABETES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-22 — — US disclosed
EP-2419413-A1 DERIVATIVES OF N-ACYL-N'-PHENYLPIPERAZINE USEFUL (INTER ALIA) FOR THE PROPHYLAXIS OR TREATMENT OF DIABETES Takeda Pharmaceutical Company Limited (JP) 2012-02-22 — — EP disclosed
WO-2010119992-A1 DERIVATIVES OF N-ACYL-N'-PHENYLPIPERAZINE USEFUL (INTER ALIA) FOR THE PROPHYLAXIS OR TREATMENT OF DIABETES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-10-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071489-A1 DERIVATIVES OF N-ACYL-N'-PHENYLPIPERAZINE USEFUL (INTER ALIA) FOR THE PROPHYLAXIS OR TREATMENT OF DIABETES RBP4, RBP1, FABP4 RBP4 1/4885TRPV1 3397/4885MEN1 3929/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.